Bevacizumab/octreotideDiarrhoea, hypertension and epistaxis: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1792卷 / 1期

关键词：

D O I：

10.1007/s40278-020-75162-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：54 / 54

相关论文

共 50 条

[21] Bevacizumab/irinotecanHepatotoxicity and proteinurea: 2 case reports
[J]. Reactions Weekly, 2016, 1618 (1) : 42 - 42
[22] Bevacizumab/irinotecanNeutropenia and mucositis: 2 case reports
[J]. Reactions Weekly, 2021, 1871 (1) : 96 - 96
[23] Bevacizumab/cetuximabDrug resistance: 2 case reports
[J]. Reactions Weekly, 2020, 1799 (1) : 98 - 98
[24] Bevacizumab/ixabepiloneNeuropathy and mucositis: 2 case reports
[J]. Reactions Weekly, 2015, 1580 (1) : 66 - 66
[25] Bevacizumab/denosumabOsteonecrosis of the jaw: 2 case reports
[J]. Reactions Weekly, 2017, 1653 (1) : 72 - 72
[26] Bevacizumab/irinotecanNausea and vomiting: 2 case reports
[J]. Reactions Weekly, 2017, 1644 (1) : 57 - 57
[27] Bevacizumab/carboplatinHypertension and proteinuria: 2 case reports
[J]. Reactions Weekly, 2019, 1754 (1) : 82 - 82
[28] Bevacizumab/sunitinibRenal disorders: 2 case reports
[J]. Reactions Weekly, 2023, 1956 (1) : 104 - 104
[29] Bevacizumab/pemetrexedVarious toxicities: 2 case reports
[J]. Reactions Weekly, 2021, 1865 (1) : 115 - 115
[30] OctreotideDiarrhoea: case report
[J]. Reactions Weekly, 2019, 1768 (1) : 260 - 260

← 1 2 3 4 5 →